Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 886-889

  Zaja, Francesco ^a   Volpetti, Stefano ^a   Chiozzotto, Marianna ^a   Puglisi, Simona ^a   Isola, Miriam ^b   Buttignol, Silvia ^a   Fanin, Renato ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; DAPSONE; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERSTITIAL PNEUMONIA; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; SALVAGE THERAPY; SERUM SICKNESS; SPLENECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; SALVAGE THERAPY; SPLENECTOMY; YOUNG ADULT;

EID: 84865359222     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23272     Document Type: Article

References (21)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386-2393.
2. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
4. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
5. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002; 69: 95-100.
6. Zaja F, Vianelli N, Sperotto A, et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003; 88: 538-546.
7. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-239.
8. Zaja F, Vianelli N, Battista M, et al. Earlier administration of Rituximab allows higher rate of long lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006; 34: 571-572.
9. Penalver FJ, Jiménez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006; 85: 400-406.
10. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, et al. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: A long-term follow-up analysis. Ann Hematol 2007; 86: 871-877.
11. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
12. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: Longterm follow-up results. Eur J Haematol 2008; 81: 165-169.
13. Patel VL, Mahévas M, Lee SY, et al. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP). Blood. 2012 May 7. [Epub ahead of print].
14. National Cancer Institute Common Toxicities Crietria Version 3.0 (CTC). 2003. Available at: http//ctep.cancer.gov/reporting/CTC-3.html.
15. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641-648.
16. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008; 371: 395-403.
17. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
18. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889-1899.
19. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
20. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115: 2755-2762.
21. Zaja F, Baccarani M, Mazza P, et al. Long term follow up analysis following front line therapy with dexamethasone or dexamethasone plus rituximab in adults with primary immune thrombocytopenia. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2415.